India’s leading drug producer Sun Pharmaceutical Industries Ltd is creating a fourth quarter profit, though reports revealed that missed analysts estimates in rising markets be more important than higher sales in India and the United States
Net profit for the world's fifth-largest generic drugs maker in the January-March quarter jumped to Rs 1,710 crore ($255 million) from Rs 890 crore in the same period a year earlier. But that was below a Thomson Reuters StarMine SmartEstimate of Rs 1,914 crore.
While U.S. sales were up 19 per cent and India sales rose 17 per cent, sales in emerging markets that include Brazil, Mexico, Russia and South Africa were flat due to adverse currency rates, the company said.
Disclaimer :
The views, opinions, positions or strategies expressed by the authors and those providing comments are theirs alone, and do not necessarily reflect the views, opinions, positions or strategies of NTIPL,
english.newstracklive.com or any employee thereof. NTIPL makes no representations as to accuracy, completeness, correctness, suitability, or validity of any information on this site and will not be liable for any errors, omissions, or delays in this information or any losses, injuries, or damages arising from its display or use.
NTIPL reserves the right to delete, edit, or alter in any manner it sees fit comments that it, in its sole discretion, deems to be obscene, offensive, defamatory, threatening, in violation of trademark, copyright or other laws, or is otherwise unacceptable.
